IDUA and Scheie syndrome: Prediction of residual enzymatic activity of IDUA variants is a major goal for early diagnosis and timely treatment of MPS I patients.Detailed molecular knowledge of how IDUA binds to its substrate can help estimate the effect of a variant on IDUA activity and predict apathogenic effect in a carrier patient.